StocksMedium•9 November 2026•
1 min read
Vir Biotechnology Stock Surges 22% on Successful Hepatitis Trial Results
Key Facts
1Vir Biotechnology stock surged 22% following the announcement of positive Phase 3 trial results for its chronic hepatitis delta treatment.
Vir Biotechnology stock surged 22% following the announcement of positive Phase 3 trial results for its chronic hepatitis delta treatment. Investing.com reported that the ECLIPSE 1 trial for the combination therapy met its primary endpoint with a 44% response rate, significantly outperforming the control group.
The clinical data showed that 79% of patients reached undetectable virus levels during the study. Vir Biotechnology closed at $12.21 on November 6, 2026, prior to this latest increase in market valuation.